ネズミの脳におけるノレピネフリンの周回と代謝は,イミプラミンを長期にわたって投与した後に発生する
Science (New York, N.Y.)
|May 15, 1970
まとめ
イミプラミンなどの三環抗うつ剤は,まずネズミの脳におけるノレピネフリンのクリアランスを遅らせます. 長期にわたってイミプラミンを使用すると,ノレピネフリンクリアランスが増加し,そのレベルが低下し,遅れた臨床抗うつ薬効果が説明される可能性があります.
科学分野:
- 神経薬理学神経薬理学について
- バイオケミストリー バイオケミストリー
背景:
- トライサイクル抗うつ剤 (TCA) は,うつ病の治療に広く使用されています.
- TCAの遅延治療効果の基礎となる正確なメカニズムは,まだ完全に理解されていません.
研究 の 目的:
- ネズミの脳におけるノレピネフリン (NE) 消失に対するイミプラミンの効果を調査する.
- イミプラミン投与期間とNEレベルとクリアランスの間の関係を調査する.
主な方法:
- ネズミにトリチエートされたノレピネフリンを内臓内投与する.
- イミプラミンの単回投与および長期投与.
- ノルエピネフリンの消失率と内生的なノルエピネフリン含有量の測定.
主要な成果:
- イミプラミンの単一投与は,ネズミの脳からトリタイテッドノレピネフリンの消失率を低下させた.
- 長期にわたるイミプラミン投与は,ノルエピネフリンの消失率の漸進的な増加につながった.
- クリアランスの増加と並行して,長期にわたるイミプラミン治療により,脳内の内生性ノルエピネフリン濃度が低下しました.
結論:
- イミプラミン治療によるノレピネフリン運動の観察された変化は,臨床抗うつ薬の有効性の時間遅れを説明する可能性がある.
- イミプラミンのノルエピネフリン代謝に対する長期的な影響は,急性効果と著しく異なる.
関連する概念動画
01:27Adrenergic Neurons: Neurotransmission
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...